<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399813</url>
  </required_header>
  <id_info>
    <org_study_id>ADXS001-06</org_study_id>
    <nct_id>NCT02399813</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal</brief_title>
  <official_title>PHASE 2 STUDY OF ADXS11-001 IN SUBJECTS WITH PERSISTENT/RECURRENT, LOCO-REGIONAL OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ANORECTAL CANAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advaxis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advaxis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations
      of ADXS11-001 in 31 and 24 subjects, respectively with persistent/recurrent, loco-regional
      or metastatic SCCA of the anorectal canal that have received at least 1 regimen for the
      treatment of advanced disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate for all subjects</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Anal Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>ADXS11-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADXS11-001</intervention_name>
    <arm_group_label>ADXS11-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have cancer of the anal canal OR rectal cancer.

          -  Must have metastatic disease or persistent/recurrent loco-regional disease

          -  Prior Therapy: may have received &lt;2 regimens for disease in the metastatic setting.
             At least one line of therapy.

          -  Be willing and able to provide written informed consent for the trial.

          -  Be â‰¥18 years of age on day of signing informed consent.

          -  Have measurable disease based on RECIST 1.1

          -  Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Demonstrate adequate organ function as defined in protocol.

          -  Females cannot be pregnant or breastfeeding and must take two methods of birth
             control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Hotline</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Hotline</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Hotline</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Hotline</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Hotline</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Information</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Hotline</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Hotline</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Information</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Advaxis Hotline</last_name>
      <phone>844-783-1529</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 18, 2017</lastchanged_date>
  <firstreceived_date>March 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
